Abstract: The use of glutathione to treat or prophylax viral, bacterial, chemical, and nuclear agents, or to treat or prophylax radiation injury to humans due to release of radioactive elements. The preferred formulation is an oral dosage form, with reduced glutathione stabilized by ascorbic acid, packaged to under controlled humidity and temperature conditions to ensure creation of charge transfer complexes that ensure consistent packaging, insignificant oxidation during packaging and subsequent normal storage, and high oral bioavailability for humans.
Abstract: The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy.
Abstract: The present invention provides novel, long-acting nanoformulated drugs and targeted drug delivery methods, and uses thereof. In one embodiment, the nanoformulated drug is a retroviral drug. In one embodiment, the nanoformulated composition comprises a nanocarrier with one or more incorporated drugs. In an exemplary embodiment, the drug is efavirenz (EFV). In a further embodiment, the nanocarrier is associated with an agent for targeting microfold cells (M-cells). In a specific embodiment, the targeting agent binds to an M-cell marker known as glycoprotein 2 (GP2). Via this mechanism, the nanodrug is targeted toward GALT.
Type:
Grant
Filed:
February 21, 2017
Date of Patent:
January 23, 2018
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Abstract: The present invention is drawn to the treatment of neonatal patients exhibiting convulsion comprising administering a composition comprising a gluconate complex, wherein said gluconate complex lacks a divalent cation such as sodium gluconate.
Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
January 9, 2018
Assignee:
Patheon Softgels, LLC
Inventors:
EmadEldin M. Hassan, Warren Walter Kindt, Roger E. Gordon
Abstract: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
Abstract: A method for microencapsulation includes isolating myofibroblasts from Wharton's jelly of a human umbilical cord. The myofibroblasts are microencapsulated using ultra-purified sodium alginate, wherein the myofibroblasts encapsulated in the sodium alginate form a three-dimensional spherical structure.
Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.
Abstract: A halogenated polysaccharide is provided having a halogen content of from about 1.0 wt. % to about 85 wt. % based on the total weight of the halogenated polysaccharide and having an average chain length of at least 6 monosaccharides. Methods of halogenating a polysaccharide to form a halogenated polysaccharide are provided that can be performed in the presence or absence of a proton solvent. Compositions such as articles of manufacture containing a halogenated polysaccharide and methods of producing such articles are also provided. The article of manufacture can also include one or more additional polymers, for example, polyvinylchloride (PVC). The article of manufacture can be, for example, a flooring tile, flooring plank, or carpet. Halogenated polysaccharides and products containing the same are bio-based, environmentally sustainable replacements or complements to existing polymers and polymer products.
Abstract: Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.
Type:
Grant
Filed:
November 25, 2011
Date of Patent:
November 21, 2017
Assignee:
Sigmoid Pharma Limited
Inventors:
Vincenzo Aversa, Ivan Coulter, Mónica Torres Rosa, Bernard Francis McDonald
Abstract: A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.
Type:
Grant
Filed:
January 6, 2016
Date of Patent:
November 21, 2017
Assignees:
Board of Regents of the University of Texas System, Neogenis Labs, Inc.
Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.
Type:
Grant
Filed:
October 27, 2014
Date of Patent:
November 21, 2017
Assignee:
Allergan Pharmaceuticals International Limited
Inventors:
Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.
Type:
Grant
Filed:
January 25, 2016
Date of Patent:
November 7, 2017
Assignee:
SUTTER WEST BAY HOSPITALS
Inventors:
Sean D. McAllister, Pierre-Yves Desprez, Anuradha Mahadevan
Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
October 10, 2017
Assignee:
Humanetics Corporation
Inventors:
David C. Egberg, Michael D. Kaytor, John C. Dykstra
Abstract: A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as acne, wrinkles, inflammation, and epidermal or musculoskeletal pain.
Abstract: The invention provides a formulation comprising (a) a drug that is poorly water-soluble, (b) at least one surfactant, and (c) at least one polar lipid, wherein the formulation is substantially free of a polar solvent, as well as methods of preparing the formulation and methods of increasing the bioavailability of a drug using the formulation.
Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.
Type:
Grant
Filed:
January 3, 2014
Date of Patent:
September 19, 2017
Assignee:
COLLEGIUM PHARMACEUTICAL, INC.
Inventors:
Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Klibanov
Abstract: A capsule endoscope includes, inside a capsule casing, an information acquiring section that acquires information on an inside of a body of a subject, a battery that supplies power, a detection section that, upon detection of introduction to the inside of the body of the subject, outputs a detection signal, a signal receiving section that receives a control signal from an outside and outputs an internal signal, and a control section that controls power supply from the battery to the information acquiring section according to the internal signal and the detection signal.
Type:
Grant
Filed:
April 8, 2013
Date of Patent:
September 12, 2017
Assignee:
OLYMPUS CORPORATION
Inventors:
Ken Sato, Fukashi Yoshizawa, Naohito Doi
Abstract: The present invention provides a composition comprising an acidified aqueous solution of (1) micro colloidal silicic acid, (2) boric acid, and (3) a water absorbing additive, having a pH value of equal to or less than 1, wherein the micro colloidal silicic acid has particle sizes in the range of 1-8 nm, especially in the range of 1.5-6 nm. The invention also provides a particulate product obtainable by the method according to claim 18, wherein the particles comprise (1) silicic acid, (2) boric acid, and (3) the water absorbing additive, and wherein at least 90% of the particles in the particulate product have particle sizes in the range of 0.3-5 ?m.
Type:
Grant
Filed:
December 4, 2015
Date of Patent:
September 12, 2017
Assignee:
Barlaa B.V.
Inventors:
Henk Maarten Laane, Walter Ferdinand Witterland
Abstract: A method of producing yeast-polyphenol ferment extract includes growing the cells of a yeast of pichia genus in a growth media to late-logarithmic growth phase, in which the carbon source in the media is exhausted; exposing the cells to a non-cytotoxic dose of polyphenol; and extracting cytoplasmic and extra-cellular components of the exposed yeast cells from the growth media.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
August 29, 2017
Assignee:
ARCH PERSONAL CARE PRODUCTS, L.P.
Inventors:
Smitha Rao, James Vincent Gruber, Geoffrey Jamison Brooks
Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
August 29, 2017
Assignee:
AcelRx Pharmaceuticals, Inc.
Inventors:
Pamela Palmer, Thomas Schreck, Stelios Tzannis, Larry Hamel, Andrew I. Poutiatine
Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
Type:
Grant
Filed:
February 4, 2016
Date of Patent:
August 29, 2017
Assignee:
Pfizer Inc.
Inventors:
Gary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, Cesar Ivan Sertzen, Vanessa Rose Shepperson
Abstract: A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble Vitamin E-derivative and at least one hydrophilic polymer. In one embodiment the storage-stable dust-free homogeneous particle formulation, consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives, with the proviso, that the sum of (a), (b), (c) and (d) equals 100% by weight of the formulation, and wherein the fines fraction with particle diameters of less than 100 ?m is less than 10% by weight. Methods of making the particulate formulation by a spray granulation process are also provided.
Type:
Grant
Filed:
September 25, 2013
Date of Patent:
August 29, 2017
Assignee:
BASF SE
Inventors:
Felicitas Guth, Karl Kolter, Michael Schönherr, Franz Weber
Abstract: Disclosed is a tablet containing anhydrous calcium hydrogen phosphate, granules (A) which contain sugars, and granules (B) which contain nuclear particles having a diameter of 10-500?m, medicine and a film coating, and which have a particle diameter of 700?m or less. The present invention enables tablet-making difficulties during the manufacture of the tablet to be suppressed. In addition, the tablet has an appropriate hardness, an excellent disintegration time, and feels very good to ingest.
Abstract: The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and improved pharmacokinetics are disclosed. A once-a-day administration of topiramate is advantageous over the multiple dose regimen both in terms of patient compliance and reduced adverse events, thus providing better treatment of the conditions for which the topiramate is indicated.
Type:
Grant
Filed:
August 31, 2007
Date of Patent:
August 29, 2017
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Avinash Nangia, Daya D. Verma, Jules Jacob
Abstract: A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
August 29, 2017
Assignee:
TWi Biotechnology, Inc.
Inventors:
Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
August 22, 2017
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Ernest George Schutt, Ronald Warren McGuire, Peter Andrew Walters, Kathleen D. A. Los
Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.
Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of delivering a compound, a composition, and the like.
Type:
Grant
Filed:
March 9, 2012
Date of Patent:
July 25, 2017
Assignee:
The Board of Trustee of the Leland Stanford Junior University
Abstract: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.
Type:
Grant
Filed:
July 18, 2016
Date of Patent:
July 18, 2017
Assignee:
Zx Pharma, LLC
Inventors:
Syed M. Shah, Daniel Hassan, Fred Hassan
Abstract: A heparin-mimicking sulfonated reverse thermal gel (SRTG) as a heparin-binding therapeutic protein delivery system. This system is designed to turn from low viscous liquid to a physical gel by exposure to body temperature alone. This allows direct deployment through a small gauge needle or catheter at target area with minimal surgical intervention. A unique aspect of this system is that it possesses a net negative charge due to the presence of sulfonate groups. This allows the SRTG to mimic heparin function, binding and preserving the bioactivity of positively charged therapeutic proteins, providing localized and sustained release of such proteins.
Type:
Grant
Filed:
October 12, 2015
Date of Patent:
July 11, 2017
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric component).
Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.
Type:
Grant
Filed:
August 27, 2014
Date of Patent:
July 11, 2017
Assignee:
Capsugel Belgium NV
Inventors:
Dominique Nicolas Cade, Xiongwei David He
Abstract: Pharmaceutical formulations for the treatment of Helicobacter pylori infection and duodenal ulcer disease and methods of preparation and medicinal use of at least one proton pump inhibitor and at least two different antibiotics within the same solid oral dosage form, whereby at least one antibiotic is encapsulated independently from at least one other antibiotic within this solid oral dosage form.
Abstract: A method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. The nanoparticle may contain a drug. The moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other methods use such libraries, use or administer such polymeric conjugates, or promote the use of such polymeric conjugates. Kits involving such polymeric conjugates are also described.
Type:
Grant
Filed:
February 13, 2015
Date of Patent:
June 27, 2017
Assignees:
Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Frank X. Gu, Omid C. Farokhzad, Robert S. Langer, Benjamin A. Teply
Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.
Abstract: The present invention relates to a pharmaceutical composition comprising a testosterone derivative having a log p of at least 5 and a vehicle, wherein the vehicle comprises a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component comprises a mono- or triglyceride of long chain fatty acids.
Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
Type:
Grant
Filed:
December 13, 2016
Date of Patent:
June 13, 2017
Assignee:
Purdue Pharma L.P.
Inventors:
Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.
Abstract: A liquid anti-aging antioxidant nutritional supplement comprising collagen, carnosine, CoEnzyme Q10 and Resveratrol particularly suitable for reducing oxidative damage to the integumentary system.
Type:
Grant
Filed:
July 29, 2015
Date of Patent:
June 6, 2017
Assignee:
MINERVA Research Labs Ltd
Inventors:
Catone Tony Sanguinetti, Thein Aung, Sara Sibilla, Vidhi Patel
Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
June 6, 2017
Assignee:
Banner Life Sciences, LLC
Inventors:
EmadEldin M. Hassan, Warren Walter Kindt, Roger E. Gordon
Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
Type:
Grant
Filed:
December 13, 2016
Date of Patent:
June 6, 2017
Assignee:
Purdue Pharma L.P.
Inventors:
Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
Type:
Grant
Filed:
April 21, 2016
Date of Patent:
June 6, 2017
Assignee:
Purdue Pharma L.P.
Inventors:
Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
Abstract: Uses of QIAPINE™ to treat internal bleeding, such as subdural hematoma and subarachinoid hemorrhage, and ocular bleeding, such as such as hyphema and vitreous hemorrhage, in a subject are described. Also described are uses of QIAPINE™ to treat vision loss resulting from hyphema or vitreous hemorrhage.
Abstract: It is provided herein modified polylactide (PLA) polymers comprising biocompatibile functional group(s) on the polymers and methods of making and using the modified PLA polymers.
Type:
Grant
Filed:
February 3, 2015
Date of Patent:
June 6, 2017
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Stephen Pacetti, Fuh-Wei Tang, Xiao Ma, Ni Ding, Derek Mortisen
Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
Type:
Grant
Filed:
February 3, 2016
Date of Patent:
May 23, 2017
Assignee:
INTEC PHARMA LTD.
Inventors:
Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
Abstract: A composition for manufacture of hard hydroxypropyl methyl cellulose capsules comprising a film forming material of hydroxypropyl methyl cellulose having a methoxy content of 27.0-30.0% (w/w), and a hydroxypropoxy content of 4.0-7.5% and as a 2% weight solution, a viscosity of 3.5-6.0 cPs at 20° C., dipping compositions, process for manufacture of hard hydroxypropyl methyl cellulose capsules according to a dip coating process and hard capsule shells.
Type:
Grant
Filed:
December 14, 2016
Date of Patent:
May 23, 2017
Assignee:
Capsugel Belgium NV
Inventors:
Dominique Nicolas Cade, David He Xiongwei
Abstract: In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.
Abstract: The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier.